RMD Open

Supplementary

Figure 1: Scatter plots between CRP-PMR-AS and ESR-PMR-AS (A), clin-PMR-AS (B) and imp-CRP PMR-AS (C) at inclusion and between CRP-PMR-AS and ESR-PMR-AS (D), clin-PMR-AS (E) and imp-CRP PMR-AS (F) at week 24 for the placebo group (n= 51). Trendlines are represented by a continuous line.







PMR: polymyalgia rheumatica; AS: activity score; ESR: erythrocyte sedimentation rate; CRP: C reactive protein; clin: clinical; imp-CRP: imputed CRP

 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
 RMD Open

 Supplemental material
 placed on this supplemental material which has been supplied by the author(s)
 RMD Open

Figure 2: Scatter plots between CRP-PMR-AS and ESR-PMR-AS (A), clin-PMR-AS (B) and imp-CRP PMR-AS (C) at inclusion and between CRP-PMR-AS and ESR-PMR-AS (D), clin-PMR-AS (E) and imp-CRP PMR-AS (F) at week 24 for the tocilizumab group (n= 49). Trendlines are represented by a continuous line.







PMR: polymyalgia rheumatica; AS: activity score; ESR: erythrocyte sedimentation rate; CRP: C reactive protein; clin: clinical; imp-CRP: imputed CRP

RMD Open

5

С

Bland Altman Plot of CRP PMR-AS and ESR PMR-AS at Inclusion on Placebo group Bland Altman Plot of CRP PMR-AS and clin PMR-AS at Inclusion on Placebo group Bland Altman Plot of CRP PMR-AS and CRP Imputed PMR-AS at Inclusion on Placebo group 15 13 ted PMR-AS 13 11. 11 CRP PMR-AS - ESR PMR-AS PMR-AS 11 -9 0 9 7 95% upper limit 7 clin Ĕ 95% upper limit 3 0 3 PMR-AS -CRP 95% upper limit 0 Mean difference 0 1 zero. zero Mean difference -1 Š zeno -1 Mean difference 08 800 -3 -0 Difference CRP 95% lower limit CRP PMR--3 0 -3 ° ଡ -5 -95% lower limit -5 0 Difference 95% lower limit -7 -7 -7 -9-Difference -9 -9 -11 --11 --11 -13 --13 --13 --15 --15 -15 50 60 10 20 30 10 20 30 40 10 20 30 40 50 CRP PMR-AS CRP PMR-AS CRP PMR-AS Е F D

represents the difference between CRP-PMR-AS and ESR-PMR-AS (A), difference between CRP-PMR-AS and clin-PMR-AS (B) and difference between CRP-PMR-AS and imp-CRP PMR-AS (C), and at week 24, in the placebo group, the y-axis shows the difference between CRP-PMR-AS and ESR-PMR-AS (D), difference between CRP-PMR-AS and clin-PMR-AS (E) and difference between CRP-PMR-AS and imp-CRP PMR-AS (F).

В

А

Figure 3: Bland–Altman plots using CRP-PMR-AS as the gold standard at inclusion in the placebo group (n=51). The y-axis







The 95% upper and lower limits are represented, and the mean differences and zero line are represented. One patient could not be represented in graph C with a difference of 20.18 and E with a difference of 20.8.

PMR: polymyalgia rheumatica; AS: activity score; ESR: erythrocyte sedimentation rate; CRP: C reactive protein; clin: clinical; imp-CRP: imputed CRP

D'Agostino J, et al. RMD Open 2024; 10:e003741. doi: 10.1136/rmdopen-2023-003741

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance

Figure 4: Bland–Altman plots using CRP-PMR-AS as the gold standard at inclusion in the tocilizumab group (n=49). The y-axis represents the difference between CRP-PMR-AS and ESR-PMR-AS (A), difference between CRP-PMR-AS and clin-PMR-AS (B) and difference between CRP-PMR-AS and imp-CRP PMR-AS (C), and at week 24, in the placebo group, the y-axis shows the difference between CRP-PMR-AS and ESR-PMR-AS (D), difference between CRP-PMR-AS and clin-PMR-AS (E) and difference between CRP-PMR-AS and imp-CRP PMR-AS (D), difference between CRP-PMR-AS (E) and difference between CRP-PMR-AS and imp-CRP PMR-AS (D), difference between CRP-PMR-AS and clin-PMR-AS (E) and difference between CRP-PMR-AS and imp-CRP PMR-AS (D).







The 95% upper and lower limits are presented, and the mean differences and zero line are presented.

PMR: polymyalgia rheumatica; AS: activity score; ESR: erythrocyte sedimentation rate; CRP: C reactive protein; clin: clinical; imp-

CRP: imputed CRP

Table 1: Intraclass correlation coefficient (ICC) between different PMR-AS at inclusion and week 24, n=100 patients

Saaraa	time	ICC	95% CI lower	95% CI
Scores			limit	upper limit
CRP-PMR-AS vs. ESR PMR-AS		0,98	0,97	0,98
CRP-PMR-AS vs. Clin PMR-AS	Inclusion Week 24	0,98	0,98	0,99
CRP-PMR-AS vs. Imp-CRP PMR-AS		0,98	0,97	0,99
CRP-PMR-AS vs. ESR PMR-AS		0,99	0,98	0,99
CRP-PMR-AS vs. Clin PMR-AS		0,98	0,97	0,98
CRP-PMR-AS vs. Imp-CRP PMR-AS		0,98	0,97	0,98

Table 2: Intraclass correlation coefficient (ICC) between different PMR in the placebo group (n=51) at inclusion and at week 24

Scores	time	ICC	95% CI lower	95% CI
			limit	upper limit
CRP-PMR-AS vs. ESR PMR-AS	Inclusion - Placebo	0,98	0,97	0,99
CRP-PMR-AS vs. Clin PMR-AS	group	0,98	0,97	0,99
CRP-PMR-AS vs. Imp-CRP PMR-AS		0,98	0,97	0,99
CRP-PMR-AS vs. ESR PMR-AS	Week 24– Placebo group	0,98	0,97	0,99
CRP-PMR-AS vs. Clin PMR-AS		0,97	0,95	0,98
CRP-PMR-AS vs. Imp-CRP PMR-AS		0,97	0,95	0,98

Table 3: Intraclass correlation coefficient (ICC) between different PMR in the tocilizumab group (n=49) at inclusion and at week 24

Scores	time	ICC	95% CI lower limit	95% Cl upper limit
CRP-PMR-AS vs. ESR PMR-AS	Inclusion –	0,97	0,96	0,98
CRP-PMR-AS vs. Clin PMR-AS	tocilizumab group	0,99	0,98	0,99
CRP-PMR-AS vs. Imp-CRP PMR-AS		0,98	0,97	0,99
CRP-PMR-AS vs. ESR PMR-AS	Week 24–	1.00	1.00	1.00
CRP-PMR-AS vs. Clin PMR-AS	tocilizumab group	1,0	1.00	1,00
CRP-PMR-AS vs. Imp-CRP PMR-AS		0,99	0,99	1.00

Table 4: Kappa coefficient between the different PMR-AS for the whole population (n=100), calculated at week 12 and week 24,

using 10 as the cutoff of CRP-PMR-AS. The results are presented as kappa with 95% confidence intervals.

	Cut off 0 to 10 vs. >10 at week 12	Cut off 0 to 10 vs. >10 at week 24	
	Kappa (CI 95%)	Kappa (CI 95%)	
CRP-PMR-AS vs. ESR-PMR	0.92 (0.84-1)	0.96 (0.90-1)	
AS	0.32 (0.0+1)	0.00 (0.00-1)	
CRP-PMR AS vs. clinical	0.89 (0.79-1)	0.91 (0.83-1)	
PMR AS	0.00 (0.70 T)	0.01 (0.00 1)	
CRP-PMR-AS vs. imp-CRP	0.90 (0.80-1)	0 82 (0 75-0 96)	
PMR-AS	0.00 (0.00 T)	0.02 (0.10 0.00)	

Table 5: Contingency tables, number of patients at inclusion in the placebo group and tocilizumab group according to the CRP-PMR-AS in the columns and clin-PMR-AS in the lines, using CRP-PMR-AS cutoffs.

clinical PMR-AS	CRP-PMR-AS			
in tocilizumab group	In tocilizumab group			
	>7 _<= 10	>10 _<= 17	> 17	Total
>7 _<= 10	1	3	1	5
>10 _ <= 17	0	12	3	15
> 17	0	0	29	29
Total	1	15	33	49
clinical PMR-AS	CRP-PMR-AS			
	In placebo group			
in placebo group	In	i placebo gro	up	
in placebo group	In >1.5 _ <= 7	o placebo gro >10 _ <= 17	up > 17	Total
in placebo group	In > 1.5 _ <= 7 1	placebo gro >10 _ <= 17 0	up > 17 0	Total 1
in placebo group >1.5 _ <= 7 >7 _ <= 10	In >1.5 _ <= 7 1 0	placebo gro >10 _ <= 17 0 1	up > 17 0 1	Total 1 2
in placebo group >1.5 _ <= 7 >7 _ <= 10 >10 _ <= 17	In >1.5 _ <= 7 1 0 0	placebo gro >10 _ <= 17 0 1 15	up > 17 0 1 0	Total 1 2 15
in placebo group >1.5 _ <= 7 >7 _ <= 10 >10 _ <= 17 > 17	In >1.5 _ <= 7 1 0 0 0	placebo gro >10 _ <= 17 0 1 15 0	up > 17 0 1 0 33	Total 1 2 15 33